Core Viewpoint - The company, Weiguang Biological, has evolved from a local factory to a leading enterprise in the blood products industry in China, emphasizing innovation as the core driving force of the industry [1][2] Group 1: Company Development - Weiguang Biological has built a product system that includes 23 specifications across 11 varieties, covering human albumin, intravenous immunoglobulin, and coagulation factors, positioning itself at the forefront of the domestic blood products industry in terms of plasma utilization and product variety [1] - The company has undertaken over 40 national and local research and technology projects, receiving multiple awards, including the Shenzhen Science and Technology Innovation Award and recognition as a national "specialized, refined, and innovative" enterprise [1] Group 2: Strategic Focus - Weiguang Biological is seizing the opportunity presented by the construction of a comprehensive national science center in Guangming District, aiming to enhance its core competitiveness through comprehensive innovation in strategy, organization, management, culture, business, and models [2] - The company plans to focus on the blood products sector and related business areas, advancing key projects such as new intravenous immunoglobulin and human fibrin adhesive, while accelerating the layout of the biopharmaceutical industry through the Weiguang Life Science Park [2]